FIELD: pharmaceuticals.
SUBSTANCE: invention relates to imidazopyridine derivatives specified in claim 1 of the formula, which inhibit the action of a protein kinase, which is at least one enzyme selected from MLK1, MLK2, and MLK3. The invention also relates to pharmaceutical preparations containing these derivatives as an active ingredient.
EFFECT: obtaining new compounds and a pharmaceutical preparation based on them which can be used in medicine for the prevention or treatment of cancer, neurodegenerative disease, non-alcoholic steatohepatitis and influenza.
9 cl, 16 dwg, 11 tbl, 98 ex
Title | Year | Author | Number |
---|---|---|---|
SUBSTITUTED IMIDAZOPYRIDINYL-AMINO-PYRIDINE COMPOUNDS, USEFUL FOR TREATMENT OF CANCER | 2010 |
|
RU2619463C2 |
CRYSTAL FORMS OF IMIDAZOLE DERIVATIVE | 2006 |
|
RU2357968C1 |
GCN2 INHIBITORS AND THEIR USE | 2019 |
|
RU2811408C2 |
BROMDOMAIN INHIBITORS | 2012 |
|
RU2671571C1 |
BROMDOMAIN INHIBITORS | 2012 |
|
RU2647592C2 |
NEW COMPOUNDS AND THEIR PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF INFLAMMATORY DISEASES | 2018 |
|
RU2785126C2 |
CXCR7 ANTAGONISTS | 2013 |
|
RU2649004C2 |
BI-ARYL-META-PYRIMIDINE KINASE INHIBITORS | 2006 |
|
RU2597364C2 |
IMIDAZOPYRIDAZINES | 2012 |
|
RU2662443C2 |
BI-ARYL-META-PYRIMIDINE KINASE INHIBITORS | 2006 |
|
RU2589878C2 |
Authors
Dates
2024-01-09—Published
2020-08-31—Filed